Median

Median Technologies Showcases eyonis LCS, AI-Driven SaMD for Lung Cancer Screening, at ECR

Median Technologies to Highlight eyonis® LCS at ECR 2026 as U.S. Commercial Launch Advances and European CE Marking Decision Nears Median Technologies today announced that it will showcase its AI-powered lung cancer screening solution, eyonis® LCS, at the upcoming European…

Read MoreMedian Technologies Showcases eyonis LCS, AI-Driven SaMD for Lung Cancer Screening, at ECR
Cure Rare

Cure Rare Disease and LGMD2L Foundation Partner Gene Therapy for Anoctamin 5 Disease

Strategic $7.65 Million Collaboration Aims to Accelerate Development of a Novel ANO5 Gene Replacement Therapy Toward Clinical Trials Cure Rare Disease (CRD), a nonprofit biotechnology organization dedicated to developing treatments for individuals with rare genetic disorders, today announced a landmark,…

Read MoreCure Rare Disease and LGMD2L Foundation Partner Gene Therapy for Anoctamin 5 Disease
MySpaLive

MySpaLive Clarifies Texas Medical Aesthetics Law Amid Misleading 2026 Claims

MySpaLive’s Compliance and Training Framework As conversations continue across the medical aesthetics industry regarding claims that Texas has “closed a med spa loophole” in 2026, MySpaLive is issuing a detailed clarification grounded in statutory authority, legislative history, and current Texas…

Read MoreMySpaLive Clarifies Texas Medical Aesthetics Law Amid Misleading 2026 Claims
SBC

SBC Medical Appoints Sheng-FU Hsiao as CTO to Lead AI-Driven Medical Infrastructure

SBC Medical Appoints Sheng-FU Hsiao as Chief Technology Officer to Accelerate AI-Driven Transformation SBC Medical Group Holdings Incorporated (“SBC Medical” or the “Company”), a global provider of comprehensive management and consulting services for medical institutions and clinic networks, has announced…

Read MoreSBC Medical Appoints Sheng-FU Hsiao as CTO to Lead AI-Driven Medical Infrastructure
Prothena

Prothena Authorizes $100M Share Repurchase Plan to Enhance Shareholder Value

Prothena’s Strategic Move to Boost Shareholder Confidence and Financial Flexibility Why are biotechnology companies increasingly turning to share repurchase plans to optimize their financial strategies? Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics,…

Read MoreProthena Authorizes $100M Share Repurchase Plan to Enhance Shareholder Value
First AzerView

First AzerView LH510 Digital Pathology Scanner Installed in the U.S.

Enhancing Diagnostic Capabilities with Advanced Imaging Technology Why is the adoption of digital pathology critical for healthcare providers today? Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic pathology services based in Plainview, New York, has partnered with Azer Scientific…

Read MoreFirst AzerView LH510 Digital Pathology Scanner Installed in the U.S.